Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.

Journal of medical virology - 1 Oct 2013

Hara Tasuku, Akuta Norio, Suzuki Fumitaka, Sezaki Hitomi, Suzuki Yoshiyuki, Hosaka Tetsuya, Kobayashi Masahiro, Kobayashi Mariko, Saitoh Satoshi, Kumada Hiromitsu

Abstract excerpt

The prevalence of hepatitis C virus (HCV) infection in elderly patients has been increasing in Japan. However, there are no reports on the safety and efficacy of the triple therapy of telaprevir, peginterferon, and ribavirin for elderly patients with chronic HCV infection. This study evaluated the safety and efficacy of triple therapy [12 weeks of telaprevir 1,500 mg/day, reduction dose, and 24 weeks of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Oligopeptides

Share to Pilot Projects

Share to Ribavirin

Source

Identifiers

PMID: 23861088
DOI: 10.1002/jmv.23673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.PMID 23861088Read ↗

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.Semantic proximity Read ↗

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Efficacy and safety of telaprevir, pegylated interferon α-2b and ribavirin triple therapy in Japanese patients infected with hepatitis C virus genotype 1b.Semantic proximity Read ↗

The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.Semantic proximity Read ↗

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b.Semantic proximity Read ↗

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Telaprevir for chronic hepatitis C with genotype 1: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.